Long BNGO - 200% or more

This is a speculative play in the Genomics industry. The technology has great promise and getting a lot of hype and recognition recently.

The risk is that they are not FDA approved and the company has cash issues. There may be a stock offering in the near future that will result in a stock price dip (-15 to 20%?) but it is only going to be even more bullish after the slight dip.

Bionano has made a targeted hire of CMO back in August which suggests that they are serious for the journey to FDA approval of Saphyr.
www.globenewswire.co...-Digital-Cytoge.html

Their product Saphyr is actually complementary to Pacific Biosciences PACB , the largest stock in the portfolio of ARK Genomic Revolution ETF (ARKG). If 2021 goes well for Bionano we could even see $15-$20 or something similar to PACB.

*RSI is above 90 which is way overbought - But this is not a technical play. May see a slight dip but I expect it to run up way higher

Kommentera:

As expected they announced an intention, and subsequently an offering at $3.05 and price has dipped around 20% since the announcement. Stock price recovered on the day itself of announcement.

Quite bullish going forward with upcoming catalyst
Next-Generation Cytogenomics Symposium JANUARY 11 - JANUARY 15

Kommentera:

Quite a positive symposium, closed a portion of it at 9.50 I think this stock may stay around $8-9 for awhile

Kommentera:

Regarding above comments: Stock consolidated at around $10 - $12 instead.

It has broke out of ascending triangle and retested $13.50. Looks bullish from here